Citation Impact
56 standout
Citing Papers
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of Bas Thijssen being referenced
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
2020
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer
2020
Author Peers
| Author | Oncology | Molecular Biology | PRM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Bas Thijssen | 202 | 137 | 70 | 21 | 451 | |
| Akio Tanaka | 1 | 42 | 18 | 291 | ||
| M. McCormick | 17 | 186 | ||||
| Erik Bertram | 1 | 13 | 241 | |||
| Gereon Raddatz | 25 | 35 | 10 | 9 | 452 | |
| Marg Cosgriff | 1 | 23 | 161 |
All Works
Loading papers...